Mahmoud Iravani
Professor of Pharmacology and Neuroscience
Mahmoud’s expertise is in vivo pharmacology, with a research portfolio focused on both motor and non-motor aspects of Parkinson’s disease (PD). His research has focussed on mechanisms of neurodegeneration notably neuroinflammation and strategies to mitigate levodopa-induced dyskinesia. His more recent work has advanced understanding of dopaminergic dysfunction and neuromuscular adaptations that underpin gut dysmotility, as well as the complex neurochemical and physiological changes contributing to non-motor symptoms such as executive dysfunction and cognitive decline. At the University of Hertfordshire, he leads a translational research programme dedicated to developing neuroprotective strategies for PD. His lab combines preclinical models with pharmacological innovation to explore disease-modifying therapies. Deeply committed to public engagement, he also plays a central role in PRONET—the Parkinson’s Research Network—enhancing dialogue between researchers, clinicians, and patients. His work exemplifies a holistic approach to PD, bridging fundamental science with clinical relevance.
